Stock AnalizMannkind Corp. MNKD
Biotechnology: Pharmaceutical Preparations · IPO 2004 · data as of November 13, 2026
Mannkind Corp. (MNKD) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to September 30, 2026 it had revenue of $413M and net income of -$75M, a net margin of -18.1%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 40% a year, a 5-year average ROIC of -61%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 63% below the current price.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $413M | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M |
| Net income | -$75M | $6M | $28M | -$12M | -$87M | -$81M | -$57M | -$52M | -$87M | -$117M | $126M |
| Free cash flow | -$78M | $14M | $33M | -$8M | -$88M | -$73M | -$29M | -$91M | -$38M | — | -$79M |
| EPS (diluted) | $-0.23 | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | $-0.27 | $-0.60 | $-1.13 | $1.36 |
| Net margin | -18.1% | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | 71.9% |
| ROIC | — | 9.7% | — | 24.6% | -216.6% | -63.3% | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $8.33, 102% above the current price; targets range from $5.00 to $13.00; the consensus rating is “Strong buy”; expected EPS is $0.01 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Mannkind stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 63% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Mannkind pay a dividend?
Not currently.
Is Mannkind a good stock to buy?
We do not give buy or sell advice. Mannkind scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.